4basebio (LON:4BB) Trading 0.1% Higher – What’s Next?

Shares of 4basebio PLC (LON:4BB) were up 0.1% on Monday . The company traded as high as GBX 1,170 ($15.12) and last traded at GBX 1,093 ($14.12). Approximately 680 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 727 shares. The stock had previously closed at GBX 1,092 ($14.11).

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a GBX 1,600 ($20.67) price target on shares of 4basebio in a research note on Thursday, March 13th.

4basebio Stock Performance

The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The firm has a market capitalization of £140.01 million, a P/E ratio of -1,401.28 and a beta of 1.09. The company’s 50 day moving average is GBX 1,151.99 and its 200-day moving average is GBX 1,246.71.

Insider Activity

In other news, insider Amy Walker acquired 1,151 shares of the firm’s stock in a transaction dated Friday, February 28th. The stock was purchased at an average price of GBX 1,120 ($14.47) per share, for a total transaction of £12,891.20 ($16,657.45). Company insiders own 68.44% of the company’s stock.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.